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RESEARCH ARTICLE Open Access
Conditional deletion of E11/podoplanin in
bone protects against load-induced
osteoarthritis
Katherine A. Staines1, Ekele Ikpegbu2, Anna E. Törnqvist3,4, Scott Dillon5, Behzad Javaheri6, Anish K. Amin7,
Dylan N. Clements5, David J. Buttle8, Andrew A. Pitsillides6 and Colin Farquharson5*
Abstract
Background: Subchondral bone (SCB) thickening is one of the earliest detectable changes in osteoarthritic joints
and is considered a potential trigger for subsequent articular cartilage degeneration. In this manuscript, we examine
whether disruption to the SCB osteocyte network contributes to the initiation and pathogenesis of osteoarthritis.
Methods: We examined expression patterns of the glycoprotein E11/podoplanin by immunohistochemical labelling
in murine, human and canine osteoarthritis models. We also examined the effects of twice-weekly administration of
Bortezomib, a proteasome inhibitor which stabilises osteocyte E11 levels, to C57/BL6 wild-type male mice (1 mg/kg/
day) for 8 weeks after surgical destabilisation of the medial meniscus. By inducing osteoarthritis-like changes in the
right knee joint of 12-week-old male E11 hypomorphic mice (and corresponding controls) using a post-traumatic
joint loading model, we also investigated whether a bone-specific E11 deletion in mice increases joint vulnerability
to osteoarthritis. Articular cartilage degradation and osteophyte formation were assessed by histology and in line
with the OARSI grading system.
Results: Our studies reveal increased E11 expression in osteocytes of human and canine osteoarthritic SCB. We
found that Bortezomib administration had no effect on surgically-induced osteoarthritis, potentially due to a lack of
the expected stabilisation of E11 in the SCB. We also found, in concordance with our previous work, wild-type mice
exhibited significant load-induced articular cartilage lesions on the lateral femoral condyle (p < 0.01) and osteophyte
formation. In contrast, E11 hypomorphic mice did not develop osteophytes or any corresponding articular lesions.
Conclusions: Overall, these data suggest that an intact osteocyte network in the SCB contributes to the
development of mechanically-driven osteoarthritis. Further, the data presented here indicate that the molecular
pathways that preserve the osteocyte network, such as those driven by E11, may be targeted to limit osteoarthritis
pathogenesis.
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Background
Osteoarthritis is a degenerative joint disease and a global
health care burden. In osteoarthritis, the articular cartilage
undergoes structural deterioration, causing joint pain, loss
of joint function and significantly reducing quality of life.
However, its underlying molecular mechanisms are not
fully understood. As such, there is an ever-growing need
for an effective disease-modifying treatment.
Although often considered secondary, subchondral
bone (SCB) thickening in osteoarthritic joints is one of
the earliest detectable changes and is now considered a
potential trigger for subsequent articular cartilage degen-
eration [1, 2]. Osteoblast-derived osteocytes are the most
numerous of all the cells within bone and have a unique
morphology with extensive dendritic processes creating
bone’s osteocyte-canalicular network. This network is
now known to orchestrate bone remodelling [3].
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However, in osteoarthritic joints, the osteocytes in the
SCB exhibit alterations to their exquisite dendritic
morphology, with fewer and more disorganised dendrites
[4]. Furthermore, other reports have noted that the ex-
pression of sclerostin, the mature osteocyte marker, is
disrupted in osteoarthritic SCB [5, 6]. Together, these
data suggest that the osteocyte may contribute a central
role to pathological SCB sclerosis in osteoarthritis and
that an intact osteocytic network is necessary for main-
taining healthy SCB architecture.
Numerous genes have been suggested to influence
osteocyte formation, one of which encodes the trans-
membrane glycoprotein E11/podoplanin. We and others
have previously shown that E11 is expressed by early
embedding osteocytes, thus identifying it as a factor
which likely contributes to the vital, early stages of
osteocyte differentiation [7–9]. It is known that mechan-
ical strain in vivo increases E11 mRNA expression [7]
and that E11 siRNA abrogates the formation of osteo-
cyte dendrites. [7]. In contrast, over-expression of E11 in
ROS 17/2.6 osteoblast-like cells has been found to pro-
mote the formation of long dendritic processes [10–12].
Furthermore, we have recently reported that E11 levels
are regulated post-translationally by proteasomal degrad-
ation and that their preservation, through the adminis-
tration of proteasome inhibitors such as Bortezomib,
leads to the induction of an osteocyte-like morphology
in MLO-A5 pre-osteocytic cells [9]. In accordance with
this, we recently showed that the hypomorphic bone-
specific ablation of E11 in mice results in disrupted
osteocytic dendrite formation, which supports a key role
for E11 in regulating the cytoskeletal changes associated
with osteocyte process formation and elongation [13].
As the formation of such dendritic processes is a key
functional feature of the normal mature osteocyte net-
work, which is perturbed in osteoarthritis [4], we have
examined herein whether disruption to the integrity of
the osteocyte dendritic processes contributes to the initi-
ation of osteoarthritis. Specifically, we investigated
whether proteasome inhibition can stabilise E11 expres-
sion in vivo to protect against the osteoarthritis that de-
velops following surgically-induced destabilisation of the
medial meniscus (DMM). Moreover, we examined
whether the bone-specific conditional deletion of E11 in
mice affects early adaptive processes and joint vulner-
ability to osteoarthritis induction by a mechanically-in-
duced post-traumatic osteoarthritis model.
Methods
Animals
C57/BL6 mice harbouring a conditional deletion of E11
in late osteoblasts (osteocalcin promoter driven; cKO;
hypomorphic with ~ 70% reduction in E11 protein ex-
pression) as well as their appropriate E11flox/flox control
littermates (WT) were kept in polypropylene cages, with
light/dark 12-h cycles, at 21 ± 2 °C, and fed ad libitum
with maintenance diet (Special Diet Services, Witham,
UK) [13]. We obtained floxed Pdpn mice from the
UCOMM/KOMP, MRC Harwell, Oxfordshire, UK and
osteocalcin-cre mice as a kind gift from Thomas Clem-
ens at John Hopkins Medicine, Baltimore, Maryland.
cKO and WT mice were generated as described previ-
ously [13]. All analyses were conducted blindly to min-
imise the effects of subjective bias. All experimental
protocols were approved by Roslin Institute’s Animal
Users Committee and the animals were maintained in
accordance with UK Home Office guidelines for the care
and use of laboratory animals.
In vivo joint loading
12-week old male cKO (n = 5) and WT (n = 3) mice were
isoflurane-anaesthetised (4% and maintained at 2% dur-
ing loading) and the right knee joint loaded as described
previously [14]. Briefly, using a servo-electric materials
testing machine (Electroforce 3100, Bose, UK), axial
compressive loads were applied through the right knee
joint via custom-made cups. All studies used a single
loading pattern in which peak loads of 11 N for the cKO
and 12 N for the WT mice (see [13]) were applied (for
0.05 s; 0.025 s rise and fall time; 9.9 s baseline hold time
at between periods of peak loading). Joints were loaded
for 40 cycles, 3 times/week for 2 weeks in the morning
and the left (non-loaded control) and right knees dis-
sected 3 days after the final loading episode. Knee joints
were fixed in 4% paraformaldehyde for 24 h at 4 °C be-
fore being stored in 70% ethanol. Mice were sacrificed
by exsanguination and confirmation of death by cervical
dislocation.
Destabilisation of the medial meniscus (DMM)
Osteoarthritis was induced in 8-week old C57/BL6 male
mice (Charles River) by surgically induced DMM under
isoflurane-induced anaesthesia (see above). Animals
were randomly allocated to treatment groups to reduce
subjective bias. We elected not to perform sham surgery
on the contralateral knee based on animal welfare
grounds since previous studies had shown no difference
in osteoarthritis scores between non-operated and sham-
operated knee joints using this model and since the pri-
mary aim of the experimental research was to evaluate
the potential protective effect of Bortezomib following
DMM [15–17]. Following transection of the medial
meniscotibial ligament, the joint capsule and skin were
closed and anaesthesia reversed. Mice then either re-
ceived twice-weekly morning intraperitoneal injections
of Bortezomib (1 mg/kg [18]; n = 8) or vehicle control
(99.7% w/v saline; n = 8) for 8 weeks at which point knee
joints were dissected, fixed in 4% paraformaldehyde for
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24 h at 4 °C, and then stored in 70% ethanol. Mice were
sacrificed by exsanguination and confirmation of death
by cervical dislocation.
Micro-computed tomography (microCT) analysis
Scans were performed with an 1172 X-Ray microtomo-
graph (Skyscan, Belgium) to evaluate the SCB. High-
resolution scans with an isotropic voxel size of 5 μm
were acquired (50 kV, 200 μA, 0.5 mm aluminium filter,
0.6° rotation angle). The projection images were recon-
structed using NRecon software version 1.6.9.4 (Skyscan,
Belgium). Each dataset was rotated in Dataviewer (Sky-
san, Belgium) to ensure similar orientation and align-
ment for analysis. Hand-drawn regions of interests
(ROI) of the SCB trabecular bone for each femur/tibia
lateral/medial compartments was first achieved [19].
SCB ROIs was subsequently selected for each compart-
ment. Analysis of SCB plate thickness and the epiphyseal
trabecular bone was achieved using 3D algorithms in
CTAn (Skyscan, Belgium) to provide: SCB plate thick-
ness (SCB Th.; mm); epiphyseal trabecular bone volume/
tissue volume (Tb. BV/TV; %); trabecular number (Tb.
N.; mm− 1); trabecular thickness (Tb. Th.; mm); trabecu-
lar separation (Tb. Sp.; mm); trabecular pattern factor
(Tb. Pf.: mm− 1) .
Human and animal osteoarthritic samples
The human SCB samples were obtained from patients
undergoing total knee replacement for osteoarthritis.
Samples (discarded femoral and tibial bone cuts) were
obtained with patient consent and ethical approval from
the NHS Lothian Bioresource. The collection, storage,
and subsequent use of human tissues are regulated in
Scotland by The Human Tissue Act (Scotland) 2006. Ca-
nine osteoarthritis samples were residual tissues col-
lected from pets undergoing surgery for the treatment of
elbow joint disease with informed consent (osteoarth-
ritis), or which had died of unrelated disease (healthy).
Consent for use was obtained from the animal owners
and ethical approval for their collection and use given by
the Veterinary Ethical Review Committee of the Univer-
sity of Edinburgh (VERC; approval 23/12). In all cases,
the joints were macroscopically evaluated for signs of
osteoarthritis.
Histological analysis
Murine left and right knee joints were decalcified, wax-
embedded and 7 μm coronal sections cut. For assess-
ment of osteoarthritis severity, multiple sections (five/
slide) from 120 μm intervals across the whole joint were
stained with Toluidine blue (0.4% in 0.1M acetate buffer,
pH 4) and counterstained with Fast Green (0.2% in
dH2O). Articular cartilage lesion severity was graded
using the well-established OARSI grading scale [20].
Scoring was conducted blindly with a second observer
scoring ~ 25% of the sections. For assessment of osteo-
clast activity, slides were stained with Goldner’s Tri-
chrome using standard procedures or for tartrate
resistant acid phosphatase (TRAP). For TRAP staining
70mg napthol AS-TR phosphate (Sigma) was dissolved
in 250 μl N-N dimethyl formamide (Sigma) and added to
50ml 0.2 M sodium acetate buffer pH 5.2. 115 mg so-
dium tartrate dihydrate (Sigma) and 70mg fast red salt
TR (Sigma) was dissolved into this solution and slides
were incubated at 37 °C for 2 h. Sections were counter-
stained in Meyer’s haematoxylin (Sigma), washed in dis-
tilled water and mounted in aqueous mounting medium
(Vector Labs). Slides were imaged using a NanoZoomer
slide scanning system (Hamamatsu) and histomorpho-
metry performed using Bioquant Osteo (Bioquant Image
Analysis Corporation).
Immunohistochemistry
For immunohistochemical localisation of E11 and scler-
ostin, sections were dewaxed in xylene and rehydrated.
Sections were incubated at 37 °C for 30 min in 1 mg/ml
trypsin for antigen demasking. Endogenous peroxidases
were blocked by treatment with 3% H2O2 in methanol
(Sigma). Species-specific amino acid sequences for E11
and sclerostin were obtained and Clustal Omega was used
to perform alignment and comparison of the mouse, hu-
man and dog sequences. The level of homology between
amino acid sequences for two different species was
expressed as mean percent identity (Additional file 1:
Table S1). As a result of this and following optimisation,
antibodies used were: E11 mouse samples (IgG polyclonal
raised in goat; R&D systems; 1/100); E11 human and ca-
nine samples (IgG polyclonal raised in sheep; R&D sys-
tems; 1/500). Sclerostin mouse samples (IgG polyclonals
raised in goat; R&D systems; 1/200); with appropriate con-
trols [9]. The Vectastain ABC universal detection kit (Vec-
tor Laboratories, Peterborough, UK) was used according
to the manufacturer’s instructions. The sections were fi-
nally dehydrated, counterstained with haematoxylin and
mounted in DePeX. All sections to be compared were im-
munostained at the same time in order to standardise
conditions and minimise any differences in antibody incu-
bation times. Positive E11 and sclerostin staining in the ar-
ticular cartilage chondrocytes and SCB osteocytes was
readily identifiable and we were therefore able to semi-
quantify staining intensity in these cell types between the
different treatment groups.
Statistical analysis
Statistical analysis of articular cartilage lesion grades
compared loaded/DMM (right) and contra-lateral con-
trol (left) joints by paired Wilcoxon’s signed-rank test.
P < 0.05 was considered statistically significant.
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Results
E11 expression is increased in human and canine
osteoarthritic SCB osteocytes
We first sought to examine the expression of E11 in the
SCB of two different osteoarthritis animal models, and in
samples from patients undergoing total knee replacement
(Fig. 1). Immunohistochemical labelling revealed that E11
expression was similar in the SCB of both surgically-in-
duced DMM and non-operated mice in both the lateral
and medial aspects of the joint (arrows, Fig. 1A). E11
immunolabelling was also observed in the articular cartil-
age chondrocytes (Fig. 1A). However, increased E11 ex-
pression was observed in the SCB osteocytes in naturally
occurring human (Fig. 1 B) and canine (Fig. 1C) osteo-
arthritis in comparison to unaffected control tissue. This
indicates that E11 expression levels are raised in osteo-
arthritic SCB osteocytes, suggesting that this may be
linked to pathology.
Administration of Bortezomib has no effect on surgically
induced osteoarthritis
We have previously shown that exposure to the prote-
asome inhibitor, Bortezomib, stabilised E11 expression
in vitro [9]. Based upon this observation, we hypothe-
sised that Bortezomib treatment would protect against
osteoarthritis pathology in vivo through an enhanced
Fig. 1 Immunohistochemical labelling for E11 in (a) DMM and non-operated C57/BL6 mice (b) human osteoarthritis samples from patients
undergoing total knee replacement (c) canine osteoarthritis samples from the medial coronoid process of the elbow. Images are representative of
n > 3. Arrows are representative of E11 positive osteocytes. Scale bar = 300 μm
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stabilisation of E11 and the promotion of osteocyte dif-
ferentiation. We found no significant differences in the
weights of mice treated with Bortezomib in comparison
to vehicle-treated mice (Fig. 2 A). There was also no sig-
nificant difference in either the maximum (Fig. 2 B) or
mean (Fig. 2 D) OARSI osteoarthritis scores for the
non-operated joints between vehicle and Bortezomib
treated mice. The DMM-operated joints showed an ex-
pected increase in the OARSI scores in comparison to the
non-operated joints (compare Fig. 2C & E to 2B & D)
however, there were no significant differences in the
OARSI scores between vehicle-treated and Bortezomib-
treated joints with DMM (Fig. 2 C, E & F).
In order to determine if there were any SCB abnor-
malities after DMM surgery in Bortezomib treated mice,
we performed microCT analysis. No significant DMM-
related differences were observed in the medial tibia
SCB plate and epiphyseal trabecular bone parameters
(Fig. 3 A–F). In contrast, Bortezomib treated mice ex-
hibited significant DMM-related increases in the SCB
thickness (P < 0.05, Fig. 3 G) and trabecular thickness
(P < 0.05, Fig. 3 J) in the lateral tibia, in comparison to
vehicle-treated mice. No significant differences were ob-
served in the other lateral tibia epiphyseal parameters.
To assess whether Bortezomib did indeed stabilise E11
expression, we performed immunolabelling for E11 in both
non-operated control and DMM-operated knee joints with
or without Bortezomib treatment. In the vehicle-treated
joints, E11 was expressed in the SCB osteocytes as ex-
pected, and also in the chondrocytes of the superficial and
middle zones of the articular cartilage (Fig. 4 A). In accord-
ance with our results in Fig. 1 A, DMM had no effect on
the SCB expression of E11 (Fig. 4 A). The administration
of Bortezomib, however, provoked decreases in the articu-
lar cartilage chondrocyte expression of E11, with no ap-
parent differences in the SCB osteocyte expression, in
both non-operated and DMM mouse joints (Fig. 4 A).
Immunolabelling for sclerostin showed positive label-
ling in the hypertrophic chondrocytes and the SCB oste-
ocytes in the non-operated joint of vehicle-treated mice
Fig. 2 (a) Weights of mice treated with Bortezomib or vehicle for days post DMM surgery (b) Maximum OARSI score in the medial and lateral
compartments of the left (contralateral control) knee joint of Bortezomib and vehicle treated mice (c) Maximum OARSI score in the medial and
lateral compartments of the right (DMM) knee joint of Bortezomib and vehicle treated mice (d) Mean OARSI score in the medial and lateral
compartments of the left non-operated (contralateral control) knee joint of Bortezomib and vehicle treated mice (e) Mean OARSI score in the
medial and lateral compartments of the right (DMM) knee joint of Bortezomib and vehicle treated mice (f) Representative histology images of
articular cartilage lesions (arrows) in the medial joint compartment. Data are presented as mean ± S.E.M (n = 8/group)
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(Fig. 4 B). With DMM, there was no apparent effect on
sclerostin expression by SCB osteocytes, however, there
was a focal loss of sclerostin expression from the hyper-
trophic chondrocytes (Fig. 4 B). This loss was more appar-
ent with Bortezomib treatment in both non-operated and
DMM mouse joints (Fig. 4 B). These data suggest that the
administration of the proteasome inhibitor Bortezomib is
unable to protect against surgically induced osteoarthritis
pathology, and has no effect on E11 expression in the
SCB, but does diminish sclerostin expression in hyper-
trophic chondrocytes of the articular cartilage.
Applied loading does not induce articular cartilage
lesions or osteophyte formation in E11 cKO mice
As the administration of Bortezomib was unable to
modify SCB E11 expression and had no effect on osteo-
arthritis induced by DMM, we next examined whether
the conditional deletion of E11 from bone modifies
Fig. 3 MicroCT analysis of the epiphyseal region of the medial tibia in DMM-operated and non-operated controls (a) subchondral bone thickness (SCB Th.)
(b) trabecular bone volume/tissue volume (Tb. BV/TV) (c) trabecular number (Tb. N.) (d) trabecular thickness (Tb. Th.) e trabecular separation (Tb. Sp.) f
trabecular pattern factor (Tb. Pf.). MicroCT analysis of the epiphyseal region of the lateral tibia in DMM-operated and non-operated controls (g)
subchondral bone thickness (SCB Th.) (h) trabecular bone volume/tissue volume (Tb. BV/TV) (I) trabecular number (Tb. N.) (J) trabecular thickness (Tb. Th.)
(k) trabecular separation (Tb. Sp.) (l) trabecular pattern factor (Tb. Pf.). Data are presented as mean ± S.E.M (n = 8/group). P< 0.05*
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susceptibility to early adaptive processes and joint vul-
nerability to osteoarthritis induction by a mechanically-
induced post-traumatic osteoarthritis model. We have
shown previously that 2 weeks of applied knee joint
loading is sufficient to induce localized articular cartilage
lesions in the lateral femur [14] and as such, we loaded
12-week-old cKO and WT mice and examined the lat-
eral femur articular cartilage for load-induced lesions.
We found that, in concordance with our previous
work, WT mice exhibited significant articular cartilage
lesions in the lateral femur, in comparison to non-loaded
limbs (p < 0.01; Fig. 5 A, C, E). However, 12-week-old
cKO mice, in contrast, did not develop significant lateral
femur lesions following 2 weeks of applied loading, in
comparison to non-loaded limbs (Fig. 5 B, D, E). How-
ever, no significant differences between loaded cKO and
WT limbs were observed. Furthermore, osteophytes
were observed by histology as expected in the loaded
knee joints of all WT mice but not in loaded knee joints
of E11 cKO mice (Fig. 6A & B). To identify baseline dif-
ferences in articular cartilage structure which may
underpin protection against load-induced lesions, we
next measured articular cartilage thickness. Surprisingly,
we found that the articular cartilage in the lateral femur
of our E11 cKO mice (non-loaded) was significantly
thinner than the WT mice (P < 0.001, Fig. 6 B). This was
however counterbalanced by a significant increase in the
thickness of the medial femur articular cartilage in the
cKO mice (P < 0.05, Fig. 6 B). Examination of the lateral
femur SCB plate surprisingly revealed no significant dif-
ferences in the bone plate thickness (Fig. 6 C). Similarly,
no significant differences were observed in the femoral
epiphyseal trabecular parameters (Fig. 6 D - H). Consist-
ent with this and with our previously published data, no
significant differences were observed in osteoclast num-
ber per bone surface (Fig. 6 I) [13]. Together, these data
suggest that the conditional deletion of E11 from bone
protects against articular cartilage lesion and osteophyte
induction in response to transient joint loading.
Discussion
Here we reveal that the bone-specific conditional dele-
tion of E11 in mice is protective against load induced
osteoarthritis pathology. This is evidenced by the restric-
tion of both the load-induced development of articular
cartilage lesions and osteophyte formation in our E11
cKO mice. We also reveal that Bortezomib fails to exert
any protection against osteoarthritis development in a
surgical model of osteoarthritis (DMM). This conclusion
was unexpected and opposite to our original hypothesis
in which we speculated that disruption to the integrity
Fig. 4 (a) E11 immunohistochemistry in the left non-operated (contralateral control) and right (DMM) knee joints of vehicle and Bortezomib
treated mice (b) sclerostin immunohistochemistry in the left non-operated (contralateral control) and right (DMM) knee joints of vehicle and
Bortezomib treated mice. Arrows are representative of E11 positive osteocytes and asterisks indicate positive E11 immunolabelling in
the chondrocytes
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of the osteocyte network would lead to greater osteo-
arthritis vulnerability.
Osteocytes are the most numerous bone cell type (>
95% of bone cells) and are essential to bone structure
and function. They have a unique morphology with
long dendritic processes creating multicellular networks
permeating the entire bone matrix [3, 21]. Historically
considered passive ‘place-holders’, osteocytes have now
emerged as versatile orchestrators of bone remodelling
as they regulate both osteoblast (bone-forming cells)
and osteoclast (bone-resorbing cells) function [22, 23].
In osteoarthritis, osteocytes are known to have a dys-
functional morphology with shorter and fewer dendritic
processes [4]. As E11 is essential for the formation of
osteocyte dendrites, we therefore hypothesised that the
ablation of E11 from bone cells would lead to SCB
thickening and exacerbated osteoarthritis pathology via
a decreased osteocyte production of the bone formation
inhibitor, sclerostin. However, in contrast to our expec-
tations, we observed the opposite outcome. Our loading
model used herein is non-invasive and does not induce
anterior cruciate ligament rupture, thus avoiding com-
plications that surgical methods have surrounding risk
of disturbances to peri-articular tissues and disease pro-
gression. Further, whilst DMM relies on permanent,
intransient destabilisation where indirect induction and
progression of articular cartilage lesions are inseparable,
joint loading in our model is controlled and transient,
allowing direct induction of lesions and separation from
progression. The data from our loading regime (6 loads
in 2 weeks) thus allows examination of load-induced
early osteoarthritis induction [14]. Our data indicate
that less efficient osteocyte differentiation and dendrite
formation, due to the hypomorphic deletion of E11,
protects against the induction of osteoarthritic articular
cartilage in response to transient loading episodes. Fur-
ther, our data presented here suggests that a disrupted
osteocyte morphology occurs in response to osteoarth-
ritis pathology, rather than being causative. This does
not however negate the possibility of E11 deficiency in-
creasing vulnerability to other stratifications of osteo-
arthritis. It is also important to consider the sample
size used for our WT mice as a potential limitation of
this study. However, using the in vivo loading model,
similar small group sizes have been used to resolve sta-
tistically significant load-related differences in articular
cartilage lesions, surface strains by digital image correl-
ation and osteocyte protein expression by immunola-
belling [14, 24, 25]. These results indicate the very high
level of reproducibility and experimental robustness of
this loading model and provides us with confidence in
our interpretation of our data.
Herein we also show that the bone specific deletion
of E11 results in reduced articular cartilage thickness
in the lateral femur. This is somewhat surprising as it
is thought that a thinner articular cartilage is more
susceptible to tensile strains, and therefore load in-
duced trauma [26, 27]. Further, as both sclerostin and
E11 are expressed in chondrocytes, and as no effects
were seen on osteoclast activity or SCB architecture,
the protection to load-induced osteoarthritis afforded
by E11 deletion in bone may, at least partially, reflect
E11’s currently undefined role in the articular
cartilage.
Fig. 5 a Mean OARSI score in the lateral femur of control and loaded knee joints of WT mice. b Mean OARSI score in the lateral femur of control
and loaded knee joints of cKO mice. c Maximum OARSI score in the lateral femur of control and loaded knee joints of WT mice. d Maximum
OARSI score in the lateral femur of control and loaded knee joints of cKO mice. e Representative histology images of articular cartilage lesions
(arrows) in the lateral femur. Data are presented as mean ± S.E.M (n > 3/group). P < 0.05*; P < 0.01**
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We have recently shown using in vitro osteocyte dif-
ferentiation that late osteoblast E11 protein levels are
regulated post-translationally by proteasome degradation
and that their preservation, through use of proteasome
inhibitors, such as Bortezomib, leads to the induction of
an osteocyte-like morphology [9]. Bortezomib is used in
vivo for the treatment of multiple myeloma and it is
undergoing clinical trials for epithelial cancer treatment
[28]. Moreover, it has been shown that Bortezomib pre-
vents the degradation of collagen type II and the induc-
tion of MMP13 in vitro, thereby suggesting that it may
have therapeutic effects in the context of osteoarthritis
Fig. 6 (a) Histology images of osteophyte formation (arrows) in loaded joints from WT mice (b) Articular cartilage thickness (LF – lateral femur, LT
– lateral tibia, MF – medial femur, MT – medial tibia). MicroCT analysis of the epiphyseal region of the lateral femur (c) subchondral bone plate
thickness (SCB Th.) (d) epiphyseal trabecular bone volume/tissue volume (Tb. BV/TV) (e) epiphyseal trabecular number (Tb. N.) (f) epiphyseal
trabecular thickness (Tb. Th.) (g) epiphyseal trabecular separation (Tb. Sp.) (h) epiphyseal trabecular pattern factor (Tb. Pf.). i Number of osteoclasts
/ bone surface. Data are presented as mean ± S.E.M (n > 3/group). P < 0.05*; P < 0.001***
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[29]. We therefore speculated that administration of the
proteasome inhibitor, Bortezomib, in vivo would exert a
protection against osteoarthritis development in an alter-
native surgically-induced model. We found that the ad-
ministration of 1 mg/kg Bortezomib, via intraperitoneal
injection, to mice undergoing DMM surgery had no ef-
fect however on osteoarthritis pathology. This concen-
tration and route of delivery has been shown previously
to successively reduce proteasome 20S and mitigate
histopathological manifestation of pancreatic injury in
mice [18]. This is in contrast to a recent publication
which showed that the administration of another prote-
asome inhibitor, MG132, protects against DMM-induced
osteoarthritis [30]. There are many possible explanations
as to why we observed these contrasting results, the
most likely of which is that MG132 and Bortezomib are
different types of proteasome inhibitors – MG132 is a
peptide aldehyde which also inhibits certain cysteine
proteinases, whereas Bortezomib is a peptide boronate
inhibitor [31]. Whilst Bortezomib is currently being
developed in the clinic, it would be interesting to
examine the effects of other proteasome inhibitors
within these subcategories to explore whether they
exert modification in osteoarthritis development. It is
also pertinent to consider our immunohistochemistry
results, which showed that the in vivo administration
of Bortezomib was not associated with any modifica-
tion in E11 expression levels in the SCB osteocyte.
The failure of in vivo Bortezomib administration to
recapitulate its in vitro effects on E11 expression may
indeed offer an explanation for lack of effect on
osteoarthritis severity. It is nonetheless intriguing that
in vivo Bortezomib treatment instead provoked de-
creased levels of E11 and sclerostin expression in ar-
ticular cartilage chondrocytes – thus indicating that
our Bortezomib dosing procedure was biologically ef-
fective in cartilage. The reasons for these observations
require further study. It must also be borne in mind
that the proteasome has manifold effects on cellular
metabolic and signalling pathways, and its effects will
not be limited to those we have analysed here.
The data generated here contribute to our under-
standing of osteoarthritis development and to our
pursuit of a disease-modifying treatment. We have
shown that the clinically-relevant drug Bortezomib,
was not found in this study to have any therapeutic
potential in a surgical model of osteoarthritis. We
have however shown that the precise control of E11
is crucial in SCB function in osteoarthritis and that
the regulatory networks controlling E11 osteocyte ex-
pression are more complex in vivo than they are in
vitro. Furthermore, the data presented here offer fur-
ther support for the role of cartilage: bone interac-
tions in the development of osteoarthritis.
Conclusions
Overall, these data suggest that an intact osteocyte net-
work in the SCB contributes to the development of
mechanically-driven osteoarthritis. Further, the data pre-
sented here indicate that the molecular pathways that
preserve the osteocyte network, such as those driven by
E11, may be targeted to limit osteoarthritis pathogenesis.
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